Trellis Bioscience Secures $9 Million in Series C Funding
Trellis Bioscience, a Redwood City-based biotechnology firm, has successfully closed a $9 million Series C funding round on July 16, 2026. The company, led by President and CEO Stefan Ryser, specializes in developing native human monoclonal antibodies (mAbs) aimed at treating infectious diseases that are difficult to manage.
Investors and Strategic Partnerships
The Series C round saw continued backing from existing investors New Science Ventures and Easton Capital. New participants in the funding include AMR Action Fund (AMRAF) and The Doctor Group of Dallas, Texas. This diverse group of investors brings valuable expertise, particularly in addressing prosthetic joint infections (PJI), which are a significant focus for Trellis.
Advancing Clinical Trials
The newly raised funds are earmarked for advancing the company's lead program—a Phase 2 trial of calpurbatug (TRL1068). This investigational treatment targets chronic prosthetic joint infections, a challenging area in infectious disease management. "Our focus is on harnessing human antibodies to address unmet medical needs," stated CEO Stefan Ryser.
Board Expansion
In line with the investment from AMR Action Fund, Junjun Gao, PhD, Principal, has joined the Trellis Board of Directors. Gao's expertise is expected to enhance the strategic direction of the company as it continues to develop its pipeline.
Innovative Antibody Technology
Trellis Bioscience has developed proprietary technology to clone antibodies from human white blood cells, minimizing the risk of toxicity commonly associated with other drug classes. This technology plays a crucial role in discovering antibodies from patients who have successfully recovered from diseases, thereby enhancing the effectiveness of treatments.
Future Outlook
With this injection of capital, Trellis Bioscience is well-positioned to continue its work on calpurbatug (TRL1068) and other promising antibody treatments. The company's pipeline also includes antiviral antibodies, one of which is currently undergoing clinical trials, demonstrating Trellis's commitment to addressing significant unmet medical needs in the field of infectious diseases.
For more information about Trellis Bioscience and their ongoing projects, visit their website.